A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours

This phase I study investigated the maximum tolerated dose and pharmacokinetics of a 3-weekly administration of BMS-188797, a paclitaxel derivate, at three dose levels (DLs) (80, 110 and 150 mg m(−2) DL), combined with cisplatin (standard dose 75 mg m(−2)). In 16 patients with advanced malignancies...

Descripción completa

Detalles Bibliográficos
Autores principales: du Bois, A, Jung, B, Loehr, A, Schaller-Kranz, T, Cohen, M, Frickhofen, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361071/
https://www.ncbi.nlm.nih.gov/pubmed/16333310
http://dx.doi.org/10.1038/sj.bjc.6602886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361071/
https://www.ncbi.nlm.nih.gov/pubmed/16333310
http://dx.doi.org/10.1038/sj.bjc.6602886

Ejemplares similares